- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03077841
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
Optimizing Preventative Adjuvant Linac-Based Radiation: The OPAL Trial a Phase II/III Study of Hypofractionated Partial Breast Irradiation in Women With Early Stage Breast Cancer
Study Overview
Status
Conditions
- Invasive Breast Carcinoma
- Early-Stage Breast Carcinoma
- Stage I Breast Cancer AJCC v7
- Stage IA Breast Cancer AJCC v7
- Stage IB Breast Cancer AJCC v7
- Stage II Breast Cancer AJCC v6 and v7
- Stage IIA Breast Cancer AJCC v6 and v7
- Stage IIB Breast Cancer AJCC v6 and v7
- Ductal Breast Carcinoma In Situ
- Stage 0 Breast Cancer AJCC v6 and v7
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. The risk of grade 2 or higher toxicity occurring during radiation and through the 6 month post-radiation follow up visit in patients treated with Optimizing Preventative Adjuvant Linac-based Radiation (OPAL) regimen.
SECONDARY OBJECTIVES:
I. To measure patient-reported cosmetic outcome, functional status, and breast pain with the OPAL regimen at 6 months, one year, two years, three years, four years, and five years after completing the OPAL regimen.
II. To measure physician-reported and photographically-assessed cosmetic outcome at 6 months, one year, two years, three years, four years, and five years after completing the OPAL regimen and to compare this to the best performing arm of 2010-0559.
III. To determine the 5-year risk of pathologically-confirmed invasive and/or in situ ipsilateral breast tumor recurrence (IBTR) for patients with ductal breast carcinoma in situ (DCIS) and early invasive breast cancer.
IV. To determine the 5-year risk of any recurrence of breast cancer, disease-free survival, and overall survival.
V. To determine maximal late (within 5 years) toxicities using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4.0 scale.
VI. To establish the feasibility of conducting multi-center radiation therapy trials within the MD Anderson Network.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients undergo hypofractionated partial breast irradiation daily for 5 days. Patients may then receive 3 additional boost fractions at the discretion of the doctor.
ARM II: Patients undergo standard breast irradiation daily for 15 days. Patients may then receive 5 additional boost fractions at the discretion of the doctor.
After completion of study treatment, patients are followed up at 6 months, and at 1.5, 3.5, and 5.5 years.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: Benjamin D Smith
- Phone Number: 713-563-2380
- Email: bsmith3@mdanderson.org
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32207
- Baptist MD Anderson Cancer Center
-
-
Georgia
-
Atlanta, Georgia, United States, 30309
- Piedmont Hospital
-
-
Indiana
-
Indianapolis, Indiana, United States, 46219
- Community Cancer Center East
-
-
Michigan
-
Saginaw, Michigan, United States, 48602
- Covenant Medical Center Harrison
-
-
New Jersey
-
Berkeley Heights, New Jersey, United States, 07922
- Summit Medical Group
-
Camden, New Jersey, United States, 08103
- Cooper Hospital University Medical Center
-
Voorhees, New Jersey, United States, 08043
- MD Anderson Cancer Center at Cooper-Voorhees
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Presbyterian Hospital
-
-
Ohio
-
Mansfield, Ohio, United States, 44903
- OhioHealth Mansfield Hospital
-
-
Texas
-
Conroe, Texas, United States, 77384
- MD Anderson in The Woodlands
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
Houston, Texas, United States, 77079
- MD Anderson West Houston
-
League City, Texas, United States, 77573
- MD Anderson League City
-
San Antonio, Texas, United States, 78229
- Saint Luke's Baptist Health System
-
Sugar Land, Texas, United States, 77478
- MD Anderson in Sugar Land
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of pathologically-confirmed invasive breast cancer or ductal carcinoma in situ
- Pathologic T stage of Tis, T1, or T2 with total size of tumor =< 3 cm (this size criteria applies to both pure DCIS and invasive tumors)
- For patients with invasive breast cancer, pathologic N stage of N0, N0 (i-), or N0 (i+); pathologic staging of the axilla is not required for patients with pure DCIS
- Treatment with breast conserving surgery
- Unifocal primary tumor based on imaging and clinical assessment; microscopic multifocality is allowed
- Final surgical margins negative defined as no tumor on ink; lobular carcinoma in situ involving the final surgical margin will be disregarded
- For invasive cancers, the tumor must be estrogen receptor positive (defined as 10% or greater expression of estrogen receptor)
- If the patient has a history of a prior non-breast cancer, all treatment for this cancer must have been completed at least one month prior to study registration and the patient must have no evidence of disease for this prior non-breast cancer
- Patients must be enrolled on the trial within 12 weeks of the later of two dates: the final breast conserving surgical procedure or administration of the last cycle of cytotoxic chemotherapy
- Final criteria for eligibility established after simulation: The tumor bed can be readily visualized on simulation computed tomography (CT) and is localized to one quadrant or region of the breast that is amenable to partial breast irradiation
Exclusion Criteria:
- Tumor invasion of the skin including dermis, chest wall, or pectoralis musculature
- Any evidence of nodal positivity beyond pathologic stage of pN0(i+)
- Systemic chemotherapy prior to final breast conserving surgery
- Patient is pregnant or nursing
- History of therapeutic irradiation to the breast, lower neck, mediastinum or other area in which there could potentially be overlap with the affected breast
- History of prior invasive or in situ cancer in either breast
- Current diagnosis of bilateral breast cancer
- History of lupus or scleroderma
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm I (hypofractionated partial breast irradiation)
Patients undergo hypofractionated partial breast irradiation daily for 5 days.
Patients may then receive 3 additional boost fractions at the discretion of the doctor.
|
Correlative studies
Ancillary studies
Undergo hypofractionated partial breast irradiation
|
Active Comparator: Arm II (hypofractionated partial breast irradiation)
Patients undergo standard breast irradiation daily for 15 days.
Patients may then receive 5 additional boost fractions at the discretion of the doctor.
|
Correlative studies
Undergo hypofractionated partial breast irradiation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk of grade 2 or higher toxicity
Time Frame: At 6 months post radiation
|
Will evaluate whether or not the risk of this outcome is higher than the risk of grade 2+ toxic events in the best performing arm of our prior clinical trial that evaluated dosing schedules of whole breast irradiation (2010-0559).
|
At 6 months post radiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient-reported cosmetic outcome
Time Frame: At 6 months, one year, two years, three years, four years, and five years after completing the optimizing preventative adjuvant linac-based radiation (OPAL) regimen
|
Patient-reported cosmetic outcome, functional status, and breast pain will be measured using the Breast Cancer Treatment Outcomes Scale (BCTOS) and will be compared for the IMPORT Low versus OPAL regimens.
Each outcome will be evaluated both as a continuous variable and as a dichotomous variable with a cutpoint of >= 2.5, indicating a moderate or greater average change in the treated breast compared to the untreated breast which serves as an internal control.
Will use descriptive statistics to summarize patient-reported cosmetic outcome, functional status, and breast pain over time.
Box plots and graphical measures will be used to display the distribution of these outcomes over time and by treatment arm.
Will conduct linear mixed models to assess changes in patient-reported cosmetic outcome, functional status, and breast pain scores over time.
A random intercept will be included to account for within-subject correlations.
|
At 6 months, one year, two years, three years, four years, and five years after completing the optimizing preventative adjuvant linac-based radiation (OPAL) regimen
|
Physician-reported and photographically-assessed cosmetic outcome
Time Frame: At 6 months, one year, two years, three years, four years, and five years after completing the OPAL regimen
|
Physician-reported cosmetic outcome, functional status, and breast pain will be measured using the Breast Cancer Treatment Outcomes Scale (BCTOS) and will be compared for the IMPORT Low versus OPAL regimens.
Each outcome will be evaluated both as a continuous variable and as a dichotomous variable with a cutpoint of >= 2.5, indicating a moderate or greater average change in the treated breast compared to the untreated breast which serves as an internal control.
Will use descriptive statistics to summarize patient-reported cosmetic outcome, functional status, and breast pain over time.
Box plots and graphical measures will be used to display the distribution of these outcomes over time and by treatment arm.
Will conduct linear mixed models to assess changes in patient-reported cosmetic outcome, functional status, and breast pain scores over time.
A random intercept will be included to account for within-subject correlations.
|
At 6 months, one year, two years, three years, four years, and five years after completing the OPAL regimen
|
Risk of pathologically-confirmed invasive and/or ipsilateral breast tumor recurrence (IBTR)
Time Frame: At 5 years
|
Will be estimated using Kaplan and Meier product-limit estimator and modeled with Cox proportional hazards regression.
IBTR will be measured from the date of treatment initiation to the date of last evaluation or IBTR.
The 5-year risk of IBTR and any recurrence will be estimated along with 95% confidence intervals.
Differences in each of these outcomes by treatment arm will be assessed using the log-rank test.
Cox proportional hazards regression and/or competing risks regression will be used if needed to account for imbalance among treatment arms with respect to risk factors for these outcomes.
|
At 5 years
|
Risk of any recurrence of breast cancer
Time Frame: At 5 years
|
Will be estimated using Kaplan and Meier product-limit estimator and modeled with Cox proportional hazards regression.
Recurrence-free survival will be measured from the date of radiation treatment initiation to the earliest date of last clinic visit, date of first recurrence, or date of death.
Differences in each of these outcomes by treatment arm will be assessed using the log-rank test.
Cox proportional hazards regression and/or competing risks regression will be used if needed to account for imbalance among treatment arms with respect to risk factors for these outcomes.
|
At 5 years
|
Disease free survival (DFS)
Time Frame: At 5 years
|
Will be estimated using Kaplan and Meier product-limit estimator and modeled with Cox proportional hazards regression.
DFS will be measured from date of treatment initiation to the earliest date of last clinic visit, date of progression, date of recurrence, date of metastasis, or date of death.
Differences in each of these outcomes by treatment arm will be assessed using the log-rank test.
Cox proportional hazards regression and/or competing risks regression will be used if needed to account for imbalance among treatment arms with respect to risk factors for these outcomes.
|
At 5 years
|
Overall survival
Time Frame: At 5 years
|
Will be estimated using Kaplan and Meier product-limit estimator and modeled with Cox proportional hazards regression.
OS will be measured from the date of treatment initiation to the earliest date of last contact or death.
Differences in each of these outcomes by treatment arm will be assessed using the log-rank test.
Cox proportional hazards regression and/or competing risks regression will be used if needed to account for imbalance among treatment arms with respect to risk factors for these outcomes.
|
At 5 years
|
Incidence of adverse events
Time Frame: Up to 5 years
|
Assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 4. Differences in National Cancer Institute CTCAE and Subjective, Objective, Management, Analytic (SOMA) toxicity by treatment arm will be evaluated using chi-square test or Fisher's exact test, as appropriate.
|
Up to 5 years
|
Feasibility of conducting multi-center radiation therapy trials within the MD Anderson Network
Time Frame: 5 years
|
The trial will be considered feasible if >= 90% of enrolled and treated patients receive the prescribed radiation dosing per protocol without deviations.
|
5 years
|
TGF-beta analysis
Time Frame: Up to 5 years
|
For this analysis, the primary outcome is grade 2 or higher breast fibrosis measured using the Subjective, Objective, Management, Analytic/Late Effects Normal Tissue Task Force scale at the 3.5 year follow up visit.
The exposure of interest is the presence of at least one copy of the C-509T allele in germline deoxyribonucleic acid (DNA).
Will also conduct exploratory analyses to assess the association of TGF-beta genotype with cosmetic outcome, other PROs, and toxicities.
T-test or rank-sum test will be used for continuous measures and chi-squared or Fishers exact test will be used for categorical measures.
|
Up to 5 years
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Benjamin D Smith, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Breast Diseases
- Neoplasms, Ductal, Lobular, and Medullary
- Carcinoma, Ductal
- Carcinoma in Situ
- Breast Neoplasms
- Carcinoma
- Breast Carcinoma In Situ
- Carcinoma, Intraductal, Noninfiltrating
- Carcinoma, Ductal, Breast
Other Study ID Numbers
- 2016-1035 (Other Identifier: M D Anderson Cancer Center)
- NCI-2017-00476 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Invasive Breast Carcinoma
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
H. Lee Moffitt Cancer Center and Research InstituteAmgenActive, not recruitingBreast Cancer | Invasive Breast Carcinoma | Invasive Ductal Breast Carcinoma | Ductal CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Fondazione MichelangeloCompletedInvasive Ductal Breast CarcinomaSpain, Ireland, Italy, Taiwan, Germany, Austria, Russian Federation
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University of ChicagoActive, not recruitingLung Metastases | Liver Metastases | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer | Invasive Lobular Breast Carcinoma | Central Nervous System Metastases | Tumors Metastatic to Brain | Lobular Breast Carcinoma in Situ | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterActive, not recruitingStage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Invasive Ductal Breast Carcinoma | Medullary Ductal Breast Carcinoma With Lymphocytic Infiltrate | Mucinous Ductal Breast Carcinoma | Papillary Ductal Breast... and other conditionsUnited States
-
Institut du Cancer de Montpellier - Val d'AurelleActive, not recruitingInvasive Breast Cancer | Breast-conserving SurgeryFrance
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaUnited States, Puerto Rico
-
St. Joseph Hospital of OrangeCompletedStage 0 Breast Carcinoma | Stage I Breast Carcinoma | Stage II Breast Carcinoma | Invasive Ductal and Invasive Lobular Breast CarcinomaUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States